Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 3—March 2015
Research

Multidrug-Resistant Tuberculosis in Europe, 2010–2011

Gunar Günther, Frank van Leth, Sofia Alexandru, Neus Altet, Korkut Avsar, Didi Bang, Raisa Barbuta, Graham Bothamley, Ana Ciobanu, Valeriu Crudu, Manfred Davilovits, Martin Dedicoat, Raquel Duarte, Gina Gualano, Heinke Kunst, Wiel de Lange, Vaira Leimane, Cecile Magis-Escurra, Anne-Marie McLaughlin, Inge Muylle, Veronika Polcová, Emanuele Pontali, Christina Popa, Rudolf Rumetshofer, Alena Skrahina, Varvara Solodovnikova, Victor Spinu, Simon Tiberi, Piret Viiklepp, Christoph LangeComments to Author , and TBNET
Author affiliations: University of Namibia School of Medicine, Windhoek, Namibia (G. Günther, C. Lange); German Center for Infection Research, Research Center Borstel, Borstel, Germany (G. Günther, C. Lange); University of Amsterdam, Amsterdam, the Netherlands (F. van Leth); Institute of Phthisiopneumology, Chisinau, Moldova (S. Alexandru, A. Ciubanu, V. Crudu); Hospital Universitari Vall d’Hebron, Barcelona, Spain (N. Altet); Jordi Gol University, Barcelona (N. Altet); Asklepios Klinik Gauting, Gauting, Germany (K. Avsar); Statens Serum Institut, Copenhagen, Denmark (D. Bang); Herlev Hospital, Herlev, Denmark (D. Bang); Balti Municipal Hospital, Balti, Moldova (R. Barbuta); Homerton University Hospital, London, UK (G. Bothamley); National TB Reference Laboratory, Chisinau, Moldova (V. Crudu); Tartu University Lung Hospital, Tartu, Estonia (M. Danilovits); University of Warwick, Coventry, UK (M. Dedicoat); Heart of England Foundation Trust, Birmingham, UK (M. Dedicoat, H. Kunst); Vila Nova de Gaia/Espinho Medical School, Vila Nova de Gaia, Portugal (R. Duarte); Porto University, Porto, Portugal (R. Duarte); National Institute for Infectious Diseases L. Spallanzani, Rome, Italy (G. Gualano); Queen Mary University, London (H. Kunst); University Medical Center Groningen, Groningen, the Netherlands (W. de Lange); Riga East University Hospital, Riga, Latvia (V. Leimane); Radboud University Medical Centre, Nijmegen/Groesbeek, the Netherlands (C. Magis-Escurra); St. James's Hospital, Dublin, Ireland (A.-M. McLaughlin); University Medical Center St. Pieter, Brussels, Belgium (I. Muylle); Thomayer University Hospital, Prague, Czech Republic (V. Polcavá); Galliera Hospital, Genoa, Italy (E. Pontali); Marius-Nasta-Institut, Bucharest, Romania (C. Popa, V. Spinu); Otto Wagner Hospital, Vienna, Austria (R. Rumetshofer); Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus (A. Skrahina, Varvara Solodovnikova); Azienda Ospedaliera della Valtellina e della Valchiavenna E. Morelli Reference Hospital for MDR and HIV-TB, Sondalo, Italy (S. Tiberi); Barts Health National Health Service Trust, London (S. Tiberi); National Institute for Health Development, Tallinn, Estonia, (P. Viiklepp); Karolinska Institute, Stockholm, Sweden (C. Lange)

Main Article

Figure

TBNET study sites in the Pan European network for study and clinical management of drug- resistant tuberculosis (TBPAN-NET) project. Stratification is based on the incidence of tuberculosis (TB) reported during 2010–2011, which matched the inclusion period of the study. Data for 2011 were obtained from the European Centre for Disease Control and Prevention (10). Low TB incidence, <20 cases/100,000 persons; intermediate TB incidence, 20–100 cases/100,000 persons; high TB incidence, >100 cas

Figure. TBNET study sites in the Pan European network for study and clinical management of drug-resistant tuberculosis (TBPAN-NET) project. Stratification is based on the incidence of tuberculosis (TB) reported during 2010–2011, which matched the inclusion period of the study. Data for 2011 were obtained from the European Centre for Disease Control and Prevention (10). Low TB incidence, <20 cases/100,000 persons; intermediate TB incidence, 20–100 cases/100,000 persons; high TB incidence, >100 cases/100,000 persons.

Main Article

References
  1. World Health Organization. Global tuberculosis report 2013. Geneva: The Organization; 2013.
  2. World Health Organization. WHO global task force outlines measures to combat XDR-TB worldwide. 2006 [cited 2014 May 10]. http://www.who.int/mediacentre/news/notes/2006/np29/en/
  3. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2014. Stockholm: The Centre; 2014.
  4. Grzybowski  S, Enarson  DA. The fate of cases of pulmonary tuberculosis under various treatment programmes. Bull Int Union Tuberc Lung Dis. 1978;53:70–5.
  5. Ahuja  SD, Ashkin  D, Avendano  M, Banerjee  R, Bauer  M, Bayona  JN, Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9:e1001300 . DOIPubMedGoogle Scholar
  6. Falzon  D, Gandhi  N, Migliori  GB, Sotgiu  G, Cox  HS, Holtz  TH, Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2013;42:156–68. DOIPubMedGoogle Scholar
  7. van der Werf  MJ, Kodmön  C, Hollo  V, Sandgren  A, Zucs  P. Drug resistance among tuberculosis cases in the European Union and European Economic Area, 2007 to 2012. Euro Surveill. 2014;19:20733 .PubMedGoogle Scholar
  8. van der Werf  MJ, Langendam  MW, Huitric  E, Manissero  D. Knowledge of tuberculosis-treatment prescription of health workers: a systematic review. Eur Respir J. 2012;39:1248–55. DOIPubMedGoogle Scholar
  9. Giehl  C, Lange  C, Duarte  R, Bothamley  G, Gerlach  C, Cirillo  DM, TBNET: collaborative research on tuberculosis in Europe. Eur J Microbiol Immunol (Bp). 2012;2:264–74.
  10. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2013. Stockholm: The Centre; 2013.
  11. World Health Organization. Definitions and reporting framework for tuberculosis—2013 revision [cited 2014 May 20]. http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
  12. Lange  C, Abubakr  I, Alfenaar  JW, Bothamley  G, Caminero  JA, Calvarho  AC, Management of patients with multidrugresistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014;44:23–63. DOIPubMedGoogle Scholar
  13. Kreuter  F, Valliant  R. A survey on survey statistics: what is done and can be done in Stata. Stata J. 2007;7:1–21.
  14. Lemeshow  S, Letenneur  L, Dartigues  JF, Lafont  S, Orgogozo  JM, Commenges  D. Illustration of analysis taking into account complex survey considerations: the association between wine consumption and dementia in the PAQUID study. Am J Epidemiol. 1998;148:298–306 . DOIPubMedGoogle Scholar
  15. van Leth  F, Kalisvaart  NA, Erkens  CG, Borgdoff  MW. Projection of the number of patients with tuberculosis in the Netherlands in 2030. Eur J Public Health. 2009;19:424–7. DOIPubMedGoogle Scholar
  16. World Health Organization. Office for Europe: roadmap to prevent and combat drug-resistant tuberculosis, 2011 [cited 2014 Sep 18]. http://www.euro.who.int/en/publications/abstracts/roadmap-to-prevent-and-combat-drug-resistant-tuberculosis
  17. Uys  PW, Warren  R, van Helden  PD, Murray  M, Victor  TC. Potential of rapid diagnosis for controlling drug-susceptible and drug-resistant tuberculosis in communities where Mycobacterium tuberculosis infections are highly prevalent. J Clin Microbiol. 2009;47:1484–90. DOIPubMedGoogle Scholar
  18. van der Werf  MJ, Langendam  MW, Huitric  E, Manissero  D. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur Respir J. 2012;39:1511–9. DOIPubMedGoogle Scholar
  19. Skrahina  A, Hurevich  H, Zalutskaya  A, Sahalchyk  E, Astrauko  A, Hoffner  S, Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ. 2013;91:36–45. DOIPubMedGoogle Scholar
  20. Royce  S, Falzon  D, van Weezenbeek  C, Dara  M, Hyder  K, Hopewell  P, Multidrug resistance in new tuberculosis patients: burden and implications. Int J Tuberc Lung Dis. 2013;17:511–3. DOIPubMedGoogle Scholar
  21. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. WHO/HTM/TB/2011.6:1-33 [cited 2014 Nov 13]. http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf
  22. Dalton  T, Cegielski  P, Akksilp  S, Asencios  L, Campos Caoili  J, Cho  SN, Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet. 2012;380:1406–17. DOIPubMedGoogle Scholar
  23. Hoffner  S. Unexpected high levels of multidrug-resistant tuberculosis present new challenges for tuberculosis control. Lancet. 2012;380:1367–9. DOIPubMedGoogle Scholar
  24. Cegielski  JP, Dalton  T, Yagui  M, Wattanaamornkiet  W, Volchenkov  GV, Via  LE, Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2014;59:1049–63. DOIPubMedGoogle Scholar
  25. Van Deun  A, Kya Jai Maug  A, Halim  MA, Kumar Das  P, Ranjan Sarker  M, Daru  P, Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182:684–92. DOIPubMedGoogle Scholar
  26. Singh  KP, Brown  M, Murphy  ME, Gillespie  SH. Moxifloxacin for tuberculosis. Lancet Infect Dis. 2012;12:176, author reply 177–8 . DOIPubMedGoogle Scholar
  27. Jacobson  KR, Tierney  DB, Jeon  CY, Mitnick  CD, Murray  MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2010;51:6–14. DOIPubMedGoogle Scholar
  28. Kliiman  K, Altraja  A. Predictors of extensively drug-resistant pulmonary tuberculosis. Ann Intern Med. 2009;150:766–75. DOIPubMedGoogle Scholar
  29. Zhao  Y, Xu  S, Wang  L, Chin  DP, Wang  S, Jiang  G, National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012;366:2161–70. DOIPubMedGoogle Scholar
  30. Hillemann  D, Hoffner  S, Cirillo  D, Drobniewski  F, Richter  E, Rusch-Gerdes  S. First evaluation after implementation of a quality control system for the second line drug susceptibility testing of Mycobacterium tuberculosis joint efforts in low and high incidence countries. PLoS ONE. 2013;8:e76765. DOIPubMedGoogle Scholar

Main Article

1Additional contributors from TBNET are listed at the end of this article.

Page created: February 18, 2015
Page updated: February 18, 2015
Page reviewed: February 18, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external